Brief: Helix Biopharma Corp Provides Clinical Development And Strategic Corporate Update

Helix Biopharma

11/02/2019 12:37

Feb 11 (Reuters) - Helix Biopharma Corp  HBP.TO :
    * HELIX BIOPHARMA CORP. PROVIDES CLINICAL DEVELOPMENT AND
STRATEGIC CORPORATE UPDATE
    * HELIX BIOPHARMA CORP - EXTENDED ITS COLLABORATION WITH
MOFFITT
CANCER CENTER AS A RESULT OF PRELIMINARY STUDIES
    * HELIX BIOPHARMA CORP - HAS BEEN IN DISCUSSIONS WITH A
GROUP THAT
INCLUDES ACM ALPHA CONSULTING MANAGEMENT AG TO DIVEST UNIT HELIX
IMMUNO-ONCOLOGY S.A.
    * HELIX BIOPHARMA CORP - ALSO BEEN IN DISCUSSIONS WITH
SEVERAL
U.S. BASED FINANCIAL ADVISORY FIRMS
    * HELIX BIOPHARMA - DISCUSSIONS WITH FINANCIAL ADVISORY
FIRMS
INCLUDE RAISING OF WORKING CAPITAL TO FINANCE COMPANY'S DRUG
DEVELOPMENT PROGRAMS
    * HELIX BIOPHARMA CORP - HELIX'S PLAN IS TO INCREASE
CLINICAL
APPLICATION OF L-DOS47 WITH VARIOUS COMBINATION TREATMENTS
    * HELIX BIOPHARMA CORP - EXPECTS TO FILE IND APPLICATION FOR
AN
L-DOS47 PANCREATIC CANCER STUDY IN COMBINATION WITH DOXORUBICIN
IN MARCH
    * HELIX BIOPHARMA CORP - CONSIDERING A NEW L-DOS47
COMBINATION
STUDY WITH PEMETREXED, CISPLATIN AND IMMUNOTHERAPY, SUCH AS
KEYTRUDA ("LDOS007")
    * HELIX BIOPHARMA - DISCUSSIONS ALSO INCLUDE EXPLORING
POSSIBLE
MERGER & ACQUISITION OPPORTUNITIES, EXPLORING U.S. LISTING
ALTERNATIVES, SUCH AS NASDAQ
    * HELIX BIOPHARMA - ENGAGED WITH GROUPS OF POTENTIAL
QUALIFIED
PARTNERS TO NEGOTIATE ON PROSPECTIVE PARTNERSHIP, ALLIANCE OR
LICENSING TRANSACTION
    * HELIX BIOPHARMA CORP - CONTINUES TO WORK WITH DELOITTE
CORPORATE
FINANCE INC

Source text for Eikon:  ID:nGNX89kNBd 
Further company coverage:  HBP.TO 

 ((Reuters.Briefs@thomsonreuters.com;))